The study met the primary endpoint, demonstrating a complete response of 89% in the ondansetron extended release injection arm vs 82% in the standard ondansetron injection arm. Topline data were ...
The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback